Start-up aims for 90% accuracy for cancer screening with AI

Lancor Scientific a London-based startup will open a new cancer research laboratory that aims to push for 90% accuracy for cancer screening by utilising AI. 

The research facility will explore the market viability and roll-out of Lancor Scientific’s patented Tumour Trace OMIS (Opto-magnetic Imaging Spectroscopy) device and the utilisation of AI technology, with the aim of delivering accurate, low-cost and near real-time cancer screening at scale.

Last month, Google announced that its AI tool, called Lymph Node Assistant (LYNA), could detect late stage breast cancer at more than 90% accuracy. Lancor Scientific has developed a device that is able to early detect cervical cancer at 90% accuracy, and can further screen for multiple types of cancers. The device detects the change of electromagnetism within tissue on quantum levels.

The new laboratory in Graz, Austria, will open in partnership with the Technical University of Graz, the Medical University of Graz and the Sigmund Freud University Vienna, to lead trials on cancer screening at a global level. Lancor Scientific will receive grants over the first five years from the Austrian Government for facilities including office, research equipment, access to academic expertise and clinical trials management.

The device will go to market in 2019 and a minimum of 10,000 devices will be produced in the next five years.  Cancer screening involves various tests for the early detection of abnormal cells in different parts of the body. Finding cancer early improves the chances for successful treatment and saves lives.

Lancor Scientific has conducted trials at Southend University Hospital NHS, and using AI, the new laboratory will remove the biological ‘noise’ (i.e. mucus) from samples, pushing for even further accuracy.

Aamir Butt, CEO of Lancor Scientific, commented: “Finding cancer early is key to saving lives. Lancor Scientific has dedicated itself to making accurate and cost effective cancer detection technology available globally. The vote of confidence from the Austrian government as well the partnership with experts at Graz Technical University allows us to continue that journey and provide a minimum of 10,000 devices within the next five years free of capital charge, with the capability of conducting 500,000 cancer tests per day. This is what we mean by making cancer screening available for everyone, everywhere.”